Literature DB >> 9313637

Human immunoglobulin ameliorates rat experimental autoimmune neuritis.

C M Gabriel1, N A Gregson, E J Redford, M Davies, K J Smith, R A Hughes.   

Abstract

Human immunoglobulin is an effective treatment for Guillain-Barré syndrome, although the mechanism of action is not understood. We have investigated the effect of human immunoglobulin in an animal model of Guillain-Barré syndrome, namely experimental autoimmune neuritis (EAN), induced in Lewis rats by immunization with bovine spinal root myelin. Human immunoglobulin administered intraperitoneally at the time of onset of disease accelerated the rate of recovery from EAN. This improvement was associated with a reduction in the titre of anti-rat myelin antibodies and may be due to earlier remyelination of demyelinated nerve fibres. This model may facilitate further investigation of the mechanism of therapeutic action of immunoglobulin in inflammatory neuropathy.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9313637     DOI： 10.1093/brain/120.9.1533

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


  9 in total

1.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

3.  The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.

Authors:  Ramona Aronovich; Aviva Katzav; Joab Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 4.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

5.  Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience.

Authors:  Lisa Sarti; Tiziana Falai; Francesco Pinto; Enrico Tendi; Sabrina Matà
Journal:  Neurol Sci       Date:  2009-03-04       Impact factor: 3.307

6.  Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth.

Authors:  Nevena Tzekova; André Heinen; Sebastian Bunk; Corinna Hermann; Hans-Peter Hartung; Birgit Reipert; Patrick Küry
Journal:  J Neuroinflammation       Date:  2015-05-29       Impact factor: 8.322

7.  Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis.

Authors:  Gerd Meyer Zu Horste; Steffen Cordes; Johannes Pfaff; Christian Mathys; Anne K Mausberg; Martin Bendszus; Mirko Pham; Hans-Peter Hartung; Bernd C Kieseier
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 8.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

9.  Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies.

Authors:  Benedikt Grünewald; Jeffrey L Bennett; Klaus V Toyka; Claudia Sommer; Christian Geis
Journal:  Int J Mol Sci       Date:  2016-08-26       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.